Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
- Conditions
- Interventions
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 720
- Registration Number
- NCT01644188
- Locations
- 🇺🇸
Investigational Site Number 840979, Los Angeles, California, United States
🇺🇸Investigational Site Number 840966, Fall River, Massachusetts, United States
🇺🇸Investigational Site Number 840946, Butte, Montana, United States
A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 152
- Registration Number
- NCT01611883
Physiological Study of Human Cholesterol Metabolism and Excretion
- Conditions
- Interventions
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Richard E. Ostlund Jr., MD
- Target Recruit Count
- 132
- Registration Number
- NCT01603758
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Sitosterolemia Metabolism
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 8
- Registration Number
- NCT01584206
- Locations
- 🇨🇦
Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 905
- Registration Number
- NCT01516879
- Locations
- 🇿🇦
Research Site, Bloemfontein, South Africa
Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01490229
- Locations
- 🇮🇹
San Raffaele Pisana, Rome, Italy
Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.
- Conditions
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 87
- Registration Number
- NCT01385631
- Locations
- 🇩🇰
Department of Cardiology, Odense University Hospital, Odense C, Denmark
Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 41
- Registration Number
- NCT01384058
- Locations
- 🇩🇪
Institut für Stoffwechselforschung, Frankfurt, Germany
🇩🇪Stephan Jacob, MD, Villingen-.Schwenningen, Germany
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1682
- Registration Number
- NCT01381679
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT01375764
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.